

Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C5426BFA17F2EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: C5426BFA17F2EN

Abstracts

The 7 major chronic lymphocytic leukemia markets reached a value of US\$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 14.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.62% during 2024-2034.

The chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which the healthy white blood cells (lymphocytes) in the bone marrow start mutating or changing into cancerous cells. This occurs when an abnormally large number of lymphocytes proliferate, pushing out normal blood cells and making it harder for the body to fight infection. The disease is classified into B lymphocytes and T lymphocytes, depending on the type of cells affected. The common symptoms associated with this ailment include enlarged and painless lymph nodes, fatigue, fever, pain in the upper left portion of the abdomen, night sweats, unexplained weight loss, easy bruising, etc. Individuals suffering from CLL may also experience frequent infections, anemia, and enlargement of the spleen. Diagnosing this condition typically requires an evaluation of the patient's medical history and clinical features. A complete blood count test that reveals a significant number of mature lymphocytes and smudge cells is often used to confirm the diagnosis. The healthcare provider may also perform several other examinations, including genomic testing, flow cytometry, imaging studies, bone marrow aspiration, biopsy, etc.

The increasing cases of genetic disorders that can cause multiple gene mutations in the DNA are primarily driving the chronic lymphocytic leukemia market. In addition to this, the expanding geriatric population, who are more vulnerable to CLL due to a greater

frequency of comorbidities, reduced organ function, and functional impairment, is also bolstering the market growth. Furthermore, the widespread adoption of monoclonal antibodies in combination with chemotherapy for treating this ailment by binding specific proteins to tumor cells and activating a mechanism that destroys them is acting as another significant growth-inducing factor. Additionally, the escalating demand for allogeneic stem cell transplantation, which can improve chances of long-term remission and boost overall health, is also creating a positive outlook for the market. Apart from this, the emerging popularity of chimeric antigen receptor T-cell therapy among patients, since it uses the body's immune cells to locate and destroy the tumor, is expected to drive the chronic lymphocytic leukemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic lymphocytic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic lymphocytic leukemia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the chronic lymphocytic leukemia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the chronic lymphocytic leukemia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the chronic lymphocytic leukemia market performed so far and how will it

perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by type across the seven major markets?

How many patients are diagnosed (2018-2034) with chronic lymphocytic leukemia across the seven major markets?

What is the size of the chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of chronic lymphocytic leukemia?

What will be the growth rate of patients across the seven major markets?

Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for chronic lymphocytic leukemia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic lymphocytic leukemia market?
What are the key regulatory events related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by status related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by phase related to the chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the chronic lymphocytic leukemia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CHRONIC LYMPHOCYTIC LEUKEMIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
- 4.5 Competitive Intelligence

5 CHRONIC LYMPHOCYTIC LEUKEMIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CHRONIC LYMPHOCYTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034?)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034?)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034?)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034?)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034?)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Epidemiology by Type (2018-2034)

- 7.6.6 Diagnosed Cases (2018-2034)
- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034?)
 - 7.7.3 Epidemiology by Age (2018-2034)
 - 7.7.4 Epidemiology by Gender (2018-2034)
 - 7.7.5 Epidemiology by Type (2018-2034)
 - 7.7.6 Diagnosed Cases (2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034?)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Epidemiology by Type (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034?)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Epidemiology by Type (2018-2034)
 - 7.9.6 Diagnosed Cases (2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 CHRONIC LYMPHOCYTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CHRONIC LYMPHOCYTIC LEUKEMIA - UNMET NEEDS

10 CHRONIC LYMPHOCYTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT

11 CHRONIC LYMPHOCYTIC LEUKEMIA - MARKETED PRODUCTS

11.1 List of Chronic Lymphocytic Leukemia Marketed Drugs Across the Top 7 Markets

11.1.1 Treanda (Bendamustine) - Astellas Pharma GmbH

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

11.1.2 Venclexta (Venetoclax) - AbbVie/Genentech

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

11.1.3 Gazyva (Obinutuzumab) - Roche

- 11.1.3.1 Drug Overview
- 11.1.3.2 Mechanism of Action
- 11.1.3.3 Regulatory Status
- 11.1.3.4 Clinical Trial Results
- 11.1.3.5 Sales Across Major Markets

11.1.4 Arzerra (Ofatumumab) - Genmab/Novartis

- 11.1.4.1 Drug Overview
- 11.1.4.2 Mechanism of Action
- 11.1.4.3 Regulatory Status
- 11.1.4.4 Clinical Trial Results
- 11.1.4.5 Sales Across Major Markets

11.1.5 Zydelig (Idelalisib) - Gilead Sciences

- 11.1.5.1 Drug Overview
- 11.1.5.2 Mechanism of Action
- 11.1.5.3 Regulatory Status
- 11.1.5.4 Clinical Trial Results
- 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CHRONIC LYMPHOCYTIC LEUKEMIA - PIPELINE DRUGS

12.1 List of Chronic Lymphocytic Leukemia Pipeline Drugs Across the Top 7 Markets

12.1.1 Epcoritamab - Genmab

- 12.1.1.1 Drug Overview

- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 Pirtobrutinib - Loxo Oncology
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 Mosunetuzumab - Genentech
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 TGR-1202 - TG Therapeutics
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Cirmtuzumab - Oncternal Therapeutics
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. CHRONIC LYMPHOCYTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 CHRONIC LYMPHOCYTIC LEUKEMIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Chronic Lymphocytic Leukemia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034?)

15.2.2 Chronic Lymphocytic Leukemia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034?)

15.3 Market Scenario - United States

15.3.1 Chronic Lymphocytic Leukemia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034?)

15.3.2 Chronic Lymphocytic Leukemia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034?)

15.3.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Chronic Lymphocytic Leukemia - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034?)

15.4.2 Chronic Lymphocytic Leukemia - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034?)

15.4.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Chronic Lymphocytic Leukemia - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034?)

15.5.2 Chronic Lymphocytic Leukemia - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034?)

15.5.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Chronic Lymphocytic Leukemia - Market Size

15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034?)
- 15.6.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034?)
- 15.6.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Chronic Lymphocytic Leukemia - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034?)
 - 15.7.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.7.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Chronic Lymphocytic Leukemia - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034?)
 - 15.8.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.8.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Chronic Lymphocytic Leukemia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034?)
 - 15.9.2 Chronic Lymphocytic Leukemia - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.9.3 Chronic Lymphocytic Leukemia - Access and Reimbursement Overview

16 CHRONIC LYMPHOCYTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C5426BFA17F2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5426BFA17F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

